Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for CT-guided percutaneous liver tumor ablation (opioid-sparing effect)
ChiCTR2100049152Phase 4Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in hepatic neoplasm (3 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Total dosage of remifentanil. Started Jul 2020; status: completed.
02
Drugs
esketamine
03
Conditions
hepatic neoplasm
Beyond the preview
Go deeper on ChiCTR2100049152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049152.